Lymphocytes

Gamida Cell Announces the Date of Its Second Quarter 2021 Financial Results and Webcast

Retrieved on: 
Wednesday, August 4, 2021
Biotechnology, Health, Stem Cells, Pharmaceutical, Oncology, Branches of biology, Biology, Immune system, Lymphocytes, Medical specialties, Biotechnology, Natural killer cell, Stem cells, Leukemia, Chimeric antigen receptor T cell

ET to review its second quarter 2021 financial results and provide an update on the company.

Key Points: 
  • ET to review its second quarter 2021 financial results and provide an update on the company.
  • Gamida Cell will also provide an update on its pipeline of NAM-enabled natural killer (NK) cell therapies, including GDA-201 and genetically-modified NK cell constructs.
  • The webcast will be available on the Investors & Media section of the Gamida Cell website at www.gamida-cell.com .
  • Gamida Cell is an advanced cell therapy company committed to cures for patients with blood cancers and serious blood diseases.

Catamaran Bio Announces Appointment of Joseph Gold, PhD, as Vice President, Technical Operations and Manufacturing

Retrieved on: 
Monday, August 2, 2021
Biotechnology, Health, Genetics, Pharmaceutical, Oncology, Branches of biology, Biology, Immune system, Lymphocytes, Natural killer cell, Cancer, Gene therapy, Chimeric antigen receptor T cell, Kite Pharma, the TAILWIND™ Platform, Catamaran Bio, THE TAILWIND™ PLATFORM, CATAMARAN BIO

Catamaran Bio, Inc. , a biotechnology company developing off-the-shelf CAR-NK cell therapies to treat cancer, today announced the appointment of Joseph Gold, PhD, as Vice President, Technical Operations and Manufacturing.

Key Points: 
  • Catamaran Bio, Inc. , a biotechnology company developing off-the-shelf CAR-NK cell therapies to treat cancer, today announced the appointment of Joseph Gold, PhD, as Vice President, Technical Operations and Manufacturing.
  • Dr. Gold is a recognized leader with more than 25 years of experience in cell and gene therapy process development and GMP manufacturing.
  • I look forward to working together with Joe as we build the infrastructure to deliver best-in-class NK cell therapies for patients with solid tumors.
  • Catamaran Bio is developing novel, off-the-shelf CAR-NK cell therapies designed to treat a broad range of cancers, including solid tumors.

NovaBiotics Announces Presentation at Upcoming Peptide Therapeutics Forum 2021

Retrieved on: 
Monday, August 2, 2021
Immune system, Branches of biology, Immunology, Biology, Lymphocytes

ABERDEEN, Scotland, Aug. 2, 2021 /PRNewswire/ -- NovaBiotics Ltd, a privately held clinical stage company developing novel immune based therapies for life-threatening and life-limiting diseases, announces that Deborah O'Neil, Ph.D., Chief Executive Officer of NovaBiotics, will deliver a presentation highlighting NovaBiotics' novel peptide drug candidates at the Peptide Therapeutics Forum 2021 taking place from August 19-20, 2021, in Basel, Switzerland.  The hybrid event will feature presentations that provide exciting new insights into peptide therapeutics.    

Key Points: 
  • "We are delighted to be presenting our immune-based peptide approach to addressing the critical need for more effective and safer treatments for fungal and bacterial infections.
  • The Peptide Therapeutics Forum will provide an interactive platform and exchange for various aspects of peptide drug development and I'm looking forward to being part of that," stated Dr. O'Neil.
  • "NovaBiotics is developing proprietary compounds based on the body's innate immune effector molecules to advance a truly revolutionary approach to combatting life-threatening and life-limiting diseases.
  • NovaBiotics Ltd is a privately held, clinical-stage biotechnology company revolutionizing the treatment of medically unmet, life-threatening and life-limiting diseases with novel, immune-based therapies.

NovaBiotics Announces Presentation at Upcoming Peptide Therapeutics Forum 2021

Retrieved on: 
Monday, August 2, 2021
Immune system, Branches of biology, Immunology, Biology, Lymphocytes

ABERDEEN, Scotland, Aug. 2, 2021 /PRNewswire/ -- NovaBiotics Ltd, a privately held clinical stage company developing novel immune based therapies for life-threatening and life-limiting diseases, announces that Deborah O'Neil, Ph.D., Chief Executive Officer of NovaBiotics, will deliver a presentation highlighting NovaBiotics' novel peptide drug candidates at the Peptide Therapeutics Forum 2021 taking place from August 19-20, 2021, in Basel, Switzerland.  The hybrid event will feature presentations that provide exciting new insights into peptide therapeutics.    

Key Points: 
  • "We are delighted to be presenting our immune-based peptide approach to addressing the critical need for more effective and safer treatments for fungal and bacterial infections.
  • The Peptide Therapeutics Forum will provide an interactive platform and exchange for various aspects of peptide drug development and I'm looking forward to being part of that," stated Dr. O'Neil.
  • "NovaBiotics is developing proprietary compounds based on the body's innate immune effector molecules to advance a truly revolutionary approach to combatting life-threatening and life-limiting diseases.
  • NovaBiotics Ltd is a privately held, clinical-stage biotechnology company revolutionizing the treatment of medically unmet, life-threatening and life-limiting diseases with novel, immune-based therapies.

CytoImmune Therapeutics Hosting Key Opinion Leader Webinar on Human Natural Killer (NK) Cell Immunotherapy

Retrieved on: 
Monday, July 19, 2021
Clinical medicine, Medicine, Branches of biology, Immune system, Virotherapy, Cancer immunotherapy, Cancer treatments, Lymphocytes, Immunotherapy, Natural killer cell, Fratricidins

MONROVIA, Calif., July 19, 2021 /PRNewswire/ -- CytoImmune Therapeutics , a clinical-stage immunotherapy company developing a novel class of NK cell-based therapies for cancer, announced today that it will host a key opinion webinar (KOL) on human natural killer (NK) cell immunotherapy on Monday, July 26at10 am Eastern Time.

Key Points: 
  • MONROVIA, Calif., July 19, 2021 /PRNewswire/ -- CytoImmune Therapeutics , a clinical-stage immunotherapy company developing a novel class of NK cell-based therapies for cancer, announced today that it will host a key opinion webinar (KOL) on human natural killer (NK) cell immunotherapy on Monday, July 26at10 am Eastern Time.
  • CytoImmune is currently developing an approach for human natural killer (NK) cell immunotherapy that involves an off-the-shelf CAR NK cell that enables the cell to recognize specific proteins or antigens that are present on the surface of tumor cells and is approaching the clinic in 2021 with lead target FLT-3 in AML.
  • CytoImmune Therapeutics is a clinical-stage biotechnology company developing a portfolio of natural killer (NK) immunotherapies designed to utilize the power of the patient's own immune system to eliminate cancer cells.
  • CytoImmune is moving towards filing the Investigational New Drug (IND) applications for novel immunotherapy programs in both solid and hematological malignancies.

Grit Biotechnology Completes Series A+ Financing to Accelerate Development of its Tumor Infiltrating Lymphocyte (TIL) Therapy Pipeline

Retrieved on: 
Thursday, July 15, 2021
Branches of biology, Health sciences, Life sciences, Oncology, Cell biology, Lymphocytes, Tumor-infiltrating lymphocytes, Therapy, Cell therapy, Iovance Biotherapeutics

SHANGHAI, China, July 15, 2021 (GLOBE NEWSWIRE) -- Grit Bio, a leading cell therapy company developing Tumor Infiltrating Lymphocytes (TIL) therapies, today announced the closing of a Series A+ financing.

Key Points: 
  • SHANGHAI, China, July 15, 2021 (GLOBE NEWSWIRE) -- Grit Bio, a leading cell therapy company developing Tumor Infiltrating Lymphocytes (TIL) therapies, today announced the closing of a Series A+ financing.
  • It is on track to bring the first TIL therapy to solid tumor patients in China.
  • The funds raised will help Grit advance its lead program into the clinic and support the development of its rich preclinical pipeline.
  • Grit Bio is a leading Chinese cell therapy company founded by cell therapy experts from Duke University and University of Southern California in 2019.

Wugen Raises $172 Million to Advance Clinical Stage Memory NK Cell Platform, Progress Best-In-Class AML Program, and Initiate Multiple Solid Tumor Trials

Retrieved on: 
Thursday, July 15, 2021
Research, Clinical trials, Stem cells, Other Health, Biotechnology, General Health, Health, Science, Oncology, Other Science, Branches of biology, Immune system, Medical specialties, Biology, Lymphocytes, Natural killer cell, Leukemia, Oncology, Acute myeloid leukemia, Chimeric antigen receptor T cell, Adaptive NK cells, Wugen, Abingworth, Tybourne, WUGEN, ABINGWORTH, TYBOURNE

The proceeds of the financing will support further clinical development of Wugens best-in-class memory natural killer (NK) cell platform and advance ongoing trials for patients with severe acute myelogenous leukemia (AML) and other oncology indications, including solid tumors.

Key Points: 
  • The proceeds of the financing will support further clinical development of Wugens best-in-class memory natural killer (NK) cell platform and advance ongoing trials for patients with severe acute myelogenous leukemia (AML) and other oncology indications, including solid tumors.
  • This significant capital raise will enable Wugen to advance its off-the-shelf cell therapies to develop a broad and differentiated oncology pipeline.
  • Wugens memory NK cell platform, with enhanced tumor-killing functionality and in vivo persistence, is designed to overcome the limitations of conventional NK cell therapies.
  • Wugen utilizes its proprietary GMP-grade fusion molecules to manufacture and scale its memory NK cell products using cells from healthy donors.

Role of Subnuclear NSrp70 in Immunity: Research at the Gwangju Institute of Science and Technology

Retrieved on: 
Thursday, July 15, 2021
Branches of biology, Medical specialties, Biology, Immune system, Immunology, T cell, Cell Cycle, Lymphocytes, Clusters of differentiation, PRDM1, Protein THEMIS

In 2011, scientists from the Gwangju Institute of Science and Technology (GIST) in Korea discovered a protein called NSrp70, which is abundant in motile T cells.

Key Points: 
  • In 2011, scientists from the Gwangju Institute of Science and Technology (GIST) in Korea discovered a protein called NSrp70, which is abundant in motile T cells.
  • With this knowledge, the scientists have been speculating about the possible role NSrp70 plays in the alternative splicing involved in T cell maturation and development.
  • They report that NSrp70 is expressed very early in the cell cycle and plays an important role in T cell development.
  • Prof. Jun sums up the findings emphatically, "Our study revealed that NSrp70 is an important regulator of T cell proliferation.

Nkarta Establishes New Combined NK Cell Therapy Manufacturing Facility / Company Headquarters

Retrieved on: 
Wednesday, July 14, 2021
Branches of biology, Biology, Medical specialties, Immune system, Lymphocytes, Biotechnology, Stem cells, Cell biology, Natural killer cell, Cell therapy, T cell, Chimeric antigen receptor T cell

The manufacturing center will be custom designed to complement Nkartas state-of-the-art technology platform and optimize the production of its multiple off-the-shelf NK cell therapy investigational products.

Key Points: 
  • The manufacturing center will be custom designed to complement Nkartas state-of-the-art technology platform and optimize the production of its multiple off-the-shelf NK cell therapy investigational products.
  • At full capacity, the manufacturing center is expected to have the flexibility to produce commercial supply of multiple cell therapy products.
  • All of Nkartas NK current cell therapy candidates are also engineered with a membrane-bound IL15, a proprietary version of a cytokine known for activating NK cell growth, to enhance the persistence and activity of the NK cells.
  • Nkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off-the-shelf natural killer (NK) cell therapies for cancer patients.

INmune Bio, Inc. Announces First Patient Treated with NK cell priming “pseudokine” INKmune in High-Risk Myelodysplastic Syndrome (MDS)

Retrieved on: 
Monday, July 12, 2021
Branches of biology, Biology, Medical specialties, Stem cells, Biotechnology, Immune system, Lymphocytes, Natural killer cell, Hematopoietic stem cell, Myelodysplastic syndrome, Clonal hypereosinophilia

MDS is a serious hematopoietic stem cell disorder in which patients have functionally defective NK cells and the level of dysfunction is predictive of overall survival.

Key Points: 
  • MDS is a serious hematopoietic stem cell disorder in which patients have functionally defective NK cells and the level of dysfunction is predictive of overall survival.
  • Current treatments, including chemotherapy and bone marrow/stem cell transplantation, have varying degrees of success, and there is no known cure for MDS.
  • In the lab we have shown that INKmune binds to multiple NK receptors and initiates the activation of over 3000 genes associated with function, trafficking, proliferation and survival.
  • No single cytokine in our hands has such broad, physiological effects, which has inspired us to refer to INKmune as a pseudokine.